ESMO Breast Cancer Virtual Meeting 2020: Results of an Interim Analysis of the PHranceSCa Study
Patients with HER2-positive early breast cancer prefer a subcutaneous fixed-dose combination of pertuzumab and trastuzumab over intravenous treatment.
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
ESMO Breast Cancer Virtual Meeting 2020: Final Results of the LOTUS Study
Findings from the phase II study support further evaluation of ipatasertib plus paclitaxel in patients with advanced triple-negative breast cancer.
FDA Approves Olaparib for HRR Gene-Mutated Metastatic Castration Resistant Prostate Cancer
FDA also approved companion diagnostic devices for selection of patients
Cancer Care Among the Syrian Refugees
A population-based model study finds substantial financial burden for host countries and humanitarian agencies.
FDA Approves Ripretinib for Advanced Gastrointestinal Stromal Tumour
Efficacy for evidence was evaluated in the INVICTUS study
Atezolizumab Combined with Bevacizumab in Unresectable HCC
Results of IMbrave150 show better overall and progression-free survival with combined treatment in patients with unresectable hepatocellular carcinoma
FDA Grants Accelerated Approval to Rucaparib for BRCA-mutated Metastatic Castration-Resistant Prostate Cancer
Evidence for efficacy is based on the results from the TRITON2 study
FDA Grants Accelerated Approval to Pomalidomide for Kaposi Sarcoma
It is approved in adult patients who are HIV-positive and HIV-negative
Prolonged Isolation May Be Detrimental for Elderly Cancer Patients During the Pandemic
With Capucine Baldini, Gustave Roussy, Villejuif, France
Fewer Cancer Diagnoses During COVID-19 Outbreak in the Netherlands
Multifactorial reasons involving patients, general practitioners and the healthcare system
FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian Cancer
FDA also approved the Myriad myChoice® CDx as a companion diagnostic for olaparib
FDA Approves Selpercatinib for Lung and Thyroid Cancers with RET Gene Mutations or Fusions
Efficacy was evaluated in a multicentre, open-label, multi-cohort LIBRETTO-001 trial